Library

eCommons

 

Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program.

Simple item page
dc.contributor.authorTchang, B.G.
dc.contributor.authorMihai, A.C.
dc.contributor.authorStefanski, A.
dc.contributor.authorGarcía-Pérez, L.E.
dc.contributor.authorMojdami, D.
dc.contributor.authorJouravskaya, I.
dc.contributor.authorGurbuz, S.
dc.contributor.authorTaylor, R.
dc.contributor.authorKaranikas, C.A.
dc.contributor.authorDunn, J.P.
dc.date.accessioned2025-05-12T17:45:56Z
dc.date.issued2025-03-12
dc.description.abstractOBJECTIVE: Increases in adiposity and adverse changes in adipose distribution commonly occur in women during midlife and with the onset of menopause. This post hoc analysis assessed body weight changes with tirzepatide by reproductive stage. METHODS: Women participants from SURMOUNT-1, -3, and -4 randomized to tirzepatide (15 mg or maximum tolerated dose) or placebo were retrospectively categorized as being in the pre-, peri-, or post-menopause stages. Body weight and waist circumference changes, the proportion of participants achieving body weight-reduction thresholds, and waist to height ratio (WHtR) category shift among those with baseline BMI < 35 kg/m<sup>2</sup> were assessed at end of study treatment. RESULTS: In SURMOUNT-1, significantly greater body weight reductions from baseline were observed with tirzepatide versus placebo in women in the premenopause (26% vs. 2%), perimenopause (23% vs. 3%), and postmenopause stages (23% vs. 3%; p < 0.001). Greater waist circumference reductions were also observed with tirzepatide across the subgroups (22 vs. 4 cm, 20 vs. 5 cm, and 20 vs. 4 cm, respectively; p < 0.001). Across the reproductive stage subgroups, 97% to 98% of participants achieved body weight reductions that were ≥5% with tirzepatide versus 29% to 33% with placebo. Furthermore, 30% to 52% of women among the reproductive stage subgroups who had baseline BMI < 35 kg/m<sup>2</sup> reached WHtR ≤ 0.49 (low central adiposity) with tirzepatide. Similar results were observed in SURMOUNT-3 and -4. CONCLUSIONS: In this post hoc analysis, tirzepatide treatment was associated with significant body weight, waist circumference, and WHtR reductions versus placebo in women living with obesity or overweight and without type 2 diabetes, irrespective of reproductive stage.en_US
dc.description.embargo2026-03-12
dc.identifier.citationTchang BG, Mihai AC, Stefanski A, García-Pérez LE, Mojdami D, Jouravskaya I, Gurbuz S, Taylor R, Karanikas CA, Dunn JP. Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program. Obesity (Silver Spring). 2025;33(5):851–60. Epub 20250312. doi: 10.1002/oby.24254. PubMed PMID: 40074721; PubMed Central PMCID: PMC12015656.en_US
dc.identifier.urihttps://hdl.handle.net/1813/116889
dc.language.isoen_US
dc.publisherWileyen_US
dc.relation.doihttps://doi.org/10.1002/oby.24254en_US
dc.relation.ispartofseriesObesity (Silver Spring, Md.)en_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectAdulten_US
dc.subjectFemaleen_US
dc.subjectHumansen_US
dc.subjectMiddle Ageden_US
dc.subjectAdiposity/drug effectsen_US
dc.subjectAnti-Obesity Agents/therapeutic useen_US
dc.subjectBody Mass Indexen_US
dc.subjectBody Weight/drug effectsen_US
dc.subjectDouble-Blind Methoden_US
dc.subjectMenopauseen_US
dc.subjectObesity/drug therapyen_US
dc.subjectPostmenopauseen_US
dc.subjectPremenopauseen_US
dc.subjectRetrospective Studiesen_US
dc.subjectTirzepatideen_US
dc.subjectWaist Circumference/drug effectsen_US
dc.subjectWeight Loss/drug effectsen_US
dc.subjectClinical Trials, Phase III as Topicen_US
dc.subjectRandomized Controlled Trials as Topicen_US
dc.subjectSecondary Data Analysisen_US
dc.subjectWCM Library Coordinated Depositen_US
dc.titleBody weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program.en_US
dc.typearticleen_US
schema.issueNumber33(5)en_US

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
40074721.pdf
Size:
1.95 MB
Format:
Adobe Portable Document Format
Download

Collections

Department of Endocrinology, Diabetes and Metabolism